iRhythm Technologies (IRTC) Fundamentals 2026 — Revenue Analysis | SniperIQ
iRhythm Technologies (IRTC) is a US-listed Healthcare company in Medical - Devices with a market capitalization of
iRhythm Technologies (IRTC) is a US-listed Healthcare company in Medical - Devices with a market capitalization of
iRhythm Technologies (IRTC) has a market capitalization of approximately
iRhythm Technologies's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 21.3x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
iRhythm Technologies runs a net profit margin of -3.5%, a gross margin of 71.0%, and an operating margin of -2.7%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
iRhythm Technologies reported revenue of $747M for fiscal year 2025, with net income of -$45M and earnings per share (EPS) of -1.39. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
iRhythm Technologies does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
iRhythm Technologies carries a debt-to-equity ratio of 4.52x and a current ratio of 5.17x, with a market beta of 1.27. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For iRhythm Technologies (IRTC) the key facts are: market cap
Get iRhythm Technologies's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.